Whooping cough

LogiX Biosciences Founder Describes Mission to ‘Solve the Unsolvable’ in Preventing Cold and Flu

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, General Health, Health, Science, Research, Infection, Dysbiosis, Nasal cavity, Whooping cough, Nose, Common, Risk, Immune system, Allergen, Vaccine, Gear

Gavin Gear, the founder and CEO of Monterey, California based startup LogiX Biosciences , issued a statement this week that the company is making significant progress in the groundbreaking field of Nasal Immune Modulation.

Key Points: 
  • Gavin Gear, the founder and CEO of Monterey, California based startup LogiX Biosciences , issued a statement this week that the company is making significant progress in the groundbreaking field of Nasal Immune Modulation.
  • “We've uncovered some tremendous breakthroughs and are looking forward to unveiling a non-steroidal, natural immune modulation approach in the near future,” said Gear.
  • “We believe we can reshape disease prevention by enhancing the body's natural defenses, focusing on the nasal cavity.
  • This isn't just symptom treatment—it's a revolution in health.”
    “Our research has been incredibly revealing and promising,” added Gear.

Measles and whooping cough outbreaks in South Africa: a sign of low vaccination coverage, experts warn

Retrieved on: 
Thursday, June 15, 2023
Vaccine, Gaps, Seizure, Cold medicine, Immunization, Vaccination, Vaccine-preventable diseases, Education, South African Medical Research Council, Parent, COVID-19, Infection, Measles vaccine, Whooping cough, Immunity, World Health Organization, Diphtheria, Research, Brain damage, Vaccine hesitancy, History, UNICEF, Measles, Cough, Death, Health, Cholera, Child, Tetanus, Sneeze, WHO, World, Safety, Pneumonia, Caregiver, Disease, Pharmaceutical industry

Worldwide, in the decades 2000-2020, childhood vaccination led to the reduction of deaths in children under 5 by 50% to 5.4 million deaths per year.

Key Points: 
  • Worldwide, in the decades 2000-2020, childhood vaccination led to the reduction of deaths in children under 5 by 50% to 5.4 million deaths per year.
  • These are deaths that would have been caused by measles, whooping cough, tetanus, polio, diphtheria, pneumonia, rotavirus diarrhoea, and other vaccine-preventable diseases.
  • Scientists from the South African Medical Research Council explain why these diseases continue to threaten children’s health in the country.

The country currently has outbreaks of several diseases. What are they?

    • It is the second most frequently reported disease outbreak in Africa after cholera.
    • Up to 10% of children under five years of age who develop measles die from complications of the disease.
    • A child requires two doses of the measles vaccine to develop protective immunity against the disease.
    • The two doses of the measles vaccine are given at 6 and 12 months of age in South Africa.

These diseases are preventable. What’s behind the spread?

    • The resurgence of vaccine-preventable diseases in South Africa is due to immunity gaps caused by low vaccination coverage.
    • A national survey conducted from July to December 2019 found that only 81% of children had received all their vaccine doses scheduled up to 12 months of age in South Africa.

What’s the cause of the gaps in immunisation?

    • This has led to an increase in the number of children who are unvaccinated or under-vaccinated.
    • Structural barriers such as vaccine availability and access to health facilities are well known to reduce vaccination coverage.
    • This has had a dramatic impact on routine immunisation services and ultimately reduced vaccine coverage over the years.

What steps can be taken to close these gaps?


    Globally, many initiatives exist to improve childhood immunization, especially in low- and middle-income countries. Within the context of the Immunization Agenda 2030 (IA2030) programme, WHO, UNICEF and Gavi, are launching the “Big Catch-Up” initiative. This initiative aims to support countries like South Africa to plan and implement intensified efforts to bolster immunisation. It has three main objectives:
    • Interventions that are focused on improving the healthcare system include cold-chain infrastructure improvements to ensure availability and access to vaccines.
    • Informing and providing education to caregivers and healthcare workers has also been effective increasing vaccination in children in cases where parents were hesitant.
    • However, not enough research is done on interventions to dispel misinformation and misconception regarding immunisation, which is one of the leading causes of vaccine hesitancy.

'Got polio?' messaging underscores a vaccine campaign's success but creates false sense of security as memories of the disease fade in US

Retrieved on: 
Friday, April 28, 2023
People, Vaccine, United Nations Foundation, Medicine, Cold medicine, Vaccine-preventable diseases, NFIP, Awareness, Life, Epidemic, Public, Polio, Neurodevelopmental disorder, COVID-19, Fear, Whooping cough, Diaphragm, Hypoesthesia, Crutch, Research, Rehabilitation, Diphtheria, History, Parent, Neck, Paralysis, Measles, Hospital, Developed country, Patient, Collection, Risk, Collective memory, Brace, Mass media, FDR, Radio, Post-polio syndrome, Diagnosis, Immunization, Headache, Death, Disease, Pharmaceutical industry, Entertainment

Thanks, Science.” Messages like this are used in memes, posters, T-shirts and even some billboards to promote routine vaccinations.

Key Points: 
  • Thanks, Science.” Messages like this are used in memes, posters, T-shirts and even some billboards to promote routine vaccinations.
  • Phrasing that aims to encourage immunizations by highlighting their accomplishments implies that some diseases are no longer a threat.
  • Moreover, a 2020 poll had found that 84% of adults viewed vaccinating children as important, a 10% decline from 2001.
  • A shift in focus to immunization in developing countries has further lulled Americans into a false sense of security.

Campaigning against a devastating disease

    • Before vaccines, polio – called infantile paralysis or poliomyelitis – was the most feared childhood disease in the U.S.
    • Frequently affecting elementary school kids, the disease sometimes presented like a cold or flu – fever, sore throat and headache.
    • Only time could reveal whether the paralysis was permanent or would recede, sometimes to return decades later as Post-Polio Syndrome.
    • High schoolers performed polio-themed plays, putting the disease itself on trial in “The People vs. Polio.” People passed around collection boxes at movie theaters and other public gatherings.

From public enemy No. 1 to success story

    • Over the next decade, the NFIP shifted its focus to widespread immunization, again using both mass media and local campaigns.
    • The repeated declaration of what polio vaccines could and were accomplishing was strategically effective in persuading more people to get their shots.
    • The American public of the 1960s and 1970s had lived through repeated polio epidemics and knew both the fear of contracting the disease and its visible aftereffects.
    • Public health rhetoric that focused on this vaccine success story worked around the world in the late 1980s and 1990s.
    • A reminder for the American public about this still dangerous disease can help ensure that “Got Polio?” does not become a serious question.

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

Retrieved on: 
Monday, January 16, 2023
Hospital, World Health Organization, Foot, Severe acute respiratory syndrome coronavirus 2, Pediatrics, SCB-2019, Commercial, COVID-19 vaccine, Oral and maxillofacial pathology, EUA, Death, Vaccination, Environment, Health, Research, Whooping cough, EMA, GMP, Development, WHO, Diphtheria, CAS-1, European Medicines Agency, RSV, Co-promotion, G&A, COVID-19, CpG, Safety, Respiratory syncytial virus, Vaccine, RMB, Omicron, Tetanus, EV71, DPT vaccine, Immunity, Pharmaceutical industry, Fine chemical, Risk management, Hand, Clover

SHANGHAI, China, Jan. 15, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today provided updates on the commercialization of SCB-2019 (CpG 1018/Alum) in China and strategic priorities in 2023.

Key Points: 
  • Commercial Launch Expected to Begin in Q1 2023: Clover has started commercial launch preparation activities in multiple key provinces and municipalities, based on Clover’s evaluation of market dynamics (including factors such as strategic fit, population size and competitive environment).
  • To date, Clover has received robust interest and demand based on the premium product profile of SCB-2019 and expects the commercial launch in these strategically prioritized areas to begin in Q1 2023.
  • At Least One In-Licensing Deal in H1 2023: At least one mid- to late-stage vaccine in-licensing deal announcement is expected in H1 2023.
  • SCB-2019: Concurrent with its commercial launch in China, Clover plans to conduct real-world effectiveness studies, with data potentially available in H2 2023.

2022 World Market for Vaccines: The Market is Valued at $202.6 Billion up from $34.1 Billion in 2017 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 7, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Vaccination, Vaccine, Diphtheria, Public health, Infection, Society, Population growth, Death, Disease, Cowpox, Haemophilus influenzae, Rubella, Quality of life, COVID-19, Smallpox, Human, Growth, WHO, Tetanus, Statistics, Forecasting, Whooping cough, Vaccine-preventable diseases, Pharmaceutical industry

However, mitigating against growth will be continuing concerns about vaccine safety, availability in developing countries and refusal to immunize.

Key Points: 
  • However, mitigating against growth will be continuing concerns about vaccine safety, availability in developing countries and refusal to immunize.
  • The report contains market forecasts, company market share and expert market estimates for vaccine categories.
  • The report also looks at trends in the market for human vaccines used to prevent various types of disease.
  • It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period.

Global Toxoid Vaccine Market Report 2022 to 2028: Featuring Astellas Pharma, Bharat Biotech, Novartis and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022
Health, Pharmaceutical, TD, Ageing, Diphtheria, Whooping cough, UIP, Prevalence, Hospital, Death, Disease, National Health Mission, TT, DT, World Health Organization, Government, ClinicalTrials.gov, Tetanus, Vaccine, Growth, Immunity, WHO, TDAP, DPT vaccine, Marketing

The global toxoid vaccine market is segmented based on disease, composition, form, and end-user.

Key Points: 
  • The global toxoid vaccine market is segmented based on disease, composition, form, and end-user.
  • Geographically, the global toxoid vaccine market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
  • The North American region is expected to hold a prominent market share in the global toxoid vaccine market.
  • Insights about market determinants that are stimulating the global toxoid vaccine market.

Pediatric Vaccines Global Markets Report 2022: Impacts of COVID-19, Market Revenue Data for 2020 and 2021, Estimates for 2022, and CAGR Projections through 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
COVID-19, Consumer, Health, Pharmaceutical, Children, BCG, Investment, Incidence, Pfizer–BioNTech COVID-19 vaccine, CoronaVac, China National Pharmaceutical Group, Chickenpox, Pfizer, Vaccine, WHO, Dros, GlaxoSmithKline, Abbott Laboratories, Whooping cough, Mumps, Gavi, Merck & Co., Hepatitis, Measles, AstraZeneca, Global health, Child, Diphtheria, Mortality, Bharat Biotech, Vaccine-preventable diseases, Organization, COVID-19, Tetanus, UNICEF, Pharmaceutical industry

This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.

Key Points: 
  • This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.
  • The report also covers market projections through 2027 and estimates market shares for key players, as well as pediatric vaccines by type and by application.
  • The report also discusses the impact of the COVID-19 pandemic on this market.
  • Vaccines are one of the most significant advances in global health and are the most cost-effective strategy to reduce child mortality.

Global Respiratory Disease Vaccine Market Report 2022: Increasing R&D Expenditure by Leading Companies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Health, Infectious Diseases, Other Health, COVID-19, Pharmaceutical, Biotechnology, Adolescence, Geography, Profile, Inactivated vaccine, Whooping cough, Porter W Anderson Jr., Vaccination, CAGR, Industry, Adult, Streptococcus pneumoniae, Global, COVID-19, USD, Infection, Infant, Observation, Ansoff Matrix, Vaccine, Pharmaceutical industry, Tuberculosis

The Global Respiratory Disease Vaccine Market is estimated to be USD 22.16 Bn in 2022 and is expected to reach USD 29.71 Bn by 2027, growing at a CAGR of 6.04%.

Key Points: 
  • The Global Respiratory Disease Vaccine Market is estimated to be USD 22.16 Bn in 2022 and is expected to reach USD 29.71 Bn by 2027, growing at a CAGR of 6.04%.
  • The Global Respiratory Disease Vaccine Market is segmented based on Infection, Type, Age Group, and Geography.
  • By Type, the market is classified into Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
  • The report offers a comprehensive evaluation of the Global Respiratory Disease Vaccine Market.

Global Conjugate Vaccine Market Report 2022: Increasing Rates of Pneumococcal Disease Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, Otitis, Adoption, Conjugation, Muscle, CDC, Sepsis, Disease, Streptococcus, Growth, Subclinical infection, Infection, CAGR, Whooping cough, WHO, Heart failure, Awareness, Ageing, Centers for Disease Control and Prevention, Paralysis, Vaccine

The increasing rates of pneumococcal disease is significantly contributing to market growth for conjugate vaccines.

Key Points: 
  • The increasing rates of pneumococcal disease is significantly contributing to market growth for conjugate vaccines.
  • The growing cases of blood infection, ear infection, sepsis across the globe, are in turn contributing to the growth of the global conjugate vaccine market.
  • The global conjugate vaccine market is segmented based on product type, disease, patient type and pathogen type.
  • Based on pathogen type the market is segmented into bacterial conjugate vaccine, viral conjugate vaccine and combination vaccine.

FDA Approves Vaccine for Use During Third Trimester of Pregnancy to Prevent Whooping Cough in Infants Younger Than Two Months of Age

Retrieved on: 
Friday, October 7, 2022
Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Dietary supplement, CDC, Disease, Risk, Cough, Hospital, Fatigue, Animal, Human services, Vaccine, Tetanus, Center for Biologics Evaluation and Research, China Biologic Products, Profile, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Whooping cough, Mother, Cosmetics, Multimedia, Diphtheria, Red, Food, Center, Immunization, Recherche et Industrie Thérapeutiques, Headache, Respiratory disease, Pain, Research, Aluminium, Safety, Smokeless tobacco, Office of Inspector General, U.S. Department of Health and Human Services, Korea Disease Control and Prevention Agency, Vaccination, Atmosphere, Death, Degenerative disease, FDA, Pregnancy, Public health, Pharmaceutical industry, Birth control, DPT vaccine, DPT vaccine

"While vaccination is the best method for providing protection, infants younger than two months of age are too young to be protected by the childhood pertussis vaccine series.

Key Points: 
  • "While vaccination is the best method for providing protection, infants younger than two months of age are too young to be protected by the childhood pertussis vaccine series.
  • This is the first vaccine approved specifically for use during pregnancy to prevent a disease in young infants whose mothers are vaccinated during pregnancy."
  • It is also called whooping cough because of the "whooping" sound that someone makes when gasping for air after a fit of coughing.
  • Today's approval is specific to use in pregnancy to prevent pertussis in infants younger than 2 months of age.